智翔金泰-U：重磅产品成功出海迈入全球化开发新阶段

国盛证券2025-06-22

海外BD 落地，海外市场启航。公司近期与Cullinan Therapeutics 签署授权许可和商业化协议，就GR1803 达成独家许可与合作协议。CullinanTherapeutics 获得GR1803 的除大中华区域（包括中国香港、中国澳门、中国台湾）以外的开发，生产，商业化权益。交易总里程碑至高7.12 亿美金，其中包括2000 万美金首付款，累计不超过2.92 亿美金的开发和注册里程碑...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2545102436?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-22 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2545102436","market":"sh","top_or_hot":-1,"title":"智翔金泰-U：重磅产品成功出海 迈入全球化开发新阶段","media":"国盛证券","content":"<div>\n<p>海外BD 落地，海外市场启航。公司近期与Cullinan Therapeutics 签署授权许可和商业化协议，就GR1803 达成独家许可与合作协议。CullinanTherapeutics 获得GR1803 的除大中华区域（包括中国香港、中国澳门、中国台湾）以外的开发，生产，商业化权益。交易总里程碑至高7.12 亿美金，其中包括2000 万美金首付款，累计不超过2.92 亿美金的开发和注册里程碑...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250622150156a716e1e9&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>智翔金泰-U：重磅产品成功出海 迈入全球化开发新阶段</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n智翔金泰-U：重磅产品成功出海 迈入全球化开发新阶段\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-22 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250622150156a716e1e9&s=b><strong>国盛证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>海外BD 落地，海外市场启航。公司近期与Cullinan Therapeutics 签署授权许可和商业化协议，就GR1803 达成独家许可与合作协议。CullinanTherapeutics 获得GR1803 的除大中华区域（包括中国香港、中国澳门、中国台湾）以外的开发，生产，商业化权益。交易总里程碑至高7.12 亿美金，其中包括2000 万美金首付款，累计不超过2.92 亿美金的开发和注册里程碑...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250622150156a716e1e9&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688443","symbol_name":"智翔金泰-U","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250622150156a716e1e9&s=b","article_id":"2545102436","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250622150156a716e1e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2545102436","pubTimestamp":1750521600,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"公司近期与Cullinan Therapeutics 签署授权许可和商业化协议，就GR1803 达成独家许可与合作协议。2024 年4 月，Cullinan Oncology 宣布进行重大调整，公司更名为Cullinan Therapeutics，并将CD3/CD19 双抗CLN-978 纳入核心研发管线，适应症从血液瘤调整为自身免疫疾病。公司国内海外各条业务线均快速拓展。看好公司长期发展，维持“买入”评级。公司龙头产品赛立奇单抗于2024 年8 月上市，预计将于2025 年参加医保谈判。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688443":"智翔金泰-U","BK0239":"医药制造"},"translate_title":"Zhixiang Jintai-U: Blockbuster products successfully went overseas and entered a new stage of global development","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688443":1},"content_text":"海外BD 落地，海外市场启航。公司近期与Cullinan Therapeutics 签署授权许可和商业化协议，就GR1803 达成独家许可与合作协议。CullinanTherapeutics 获得GR1803 的除大中华区域（包括中国香港、中国澳门、中国台湾）以外的开发，生产，商业化权益。交易总里程碑至高7.12 亿美金，其中包括2000 万美金首付款，累计不超过2.92 亿美金的开发和注册里程碑付款，累计不超过4 亿美金的基于净销售额的里程碑付款。合作伙伴为自免治疗新贵，广泛布局多类自免CD3 双抗。2024 年4 月，Cullinan Oncology 宣布进行重大调整，公司更名为Cullinan Therapeutics，并将CD3/CD19 双抗CLN-978 纳入核心研发管线，适应症从血液瘤调整为自身免疫疾病。本次合作靶点的GR1803 靶点为CD3/BCMA，体现Cullinan Therapeutic 有意进一步增强自免TCE 双抗战略布局。公司国内海外各条业务线均快速拓展。近日公司GR2001 用于破伤风的被动免疫适应症的三期临床达到主要疗效终点，公司已向国家药品监督管理局药品审评中心提交了新药上市申请并获得受理。在2025 年1 月，赛立奇单抗用于成人常规治疗疗效欠佳的强直性脊柱炎（放射学阳性中轴型脊柱关节炎）适应症获批上市。盈利预测：公司目前在国内海外各个领域管线推进快速发展。看好公司长期发展，维持“买入”评级。公司龙头产品赛立奇单抗于2024 年8 月上市，预计将于2025 年参加医保谈判。我们预计公司2025-2027 年营业收入分别为2.06 亿元、5.00 亿元、10.78 亿元；归母净利润分别为-6.22 亿元、-4.73 亿元、-2.75 亿元。风险提示：临床进展不及预期风险，政策风险，产品销售不及预期风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2545102436","isCrawlerRequest":true}

智翔金泰-U：重磅产品成功出海 迈入全球化开发新阶段

精彩评论

智翔金泰-U：重磅产品成功出海迈入全球化开发新阶段